The Asp477Gly mutation in the 7TM binding-site of SMO (Figure 4A), initially isolated from a patient whose tumor had become resistant to vismodegib, reduces binding and responsiveness to a subset of 7TM ligands, including SAG and vismodegib (Yauch et al., 2009). Here, SAG is linked to neoplasm.